NASDAQ · Health care

Gyre Therapeutics, Inc. (GYRE)

Gyre Therapeutics, Inc. brought in $116.7M of revenue over the twelve months to September 30, 2026, up 3.8% from a year earlier. It posted a net loss of $30.1M. In fiscal 2025 capital spending exceeded operating cash flow by $180K. At September 30, 2026 it held $41.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 6, 2026.

Watch GYRE in 60 seconds

Price

$4.65

-2.31% on the day · November 9, 2026

52-week range $3.97 to $9.14

Market cap

$518.5M

Revenue (last 12 months)

$116.7M

+3.8% year on year

Net margin

-25.8%

P/E

232.5

on FY2025 diluted EPS

Key facts about Gyre Therapeutics, Inc.

Net worth: Gyre Therapeutics, Inc. has a market value (market cap) of $518.5M at the latest share price, and shareholders' equity of $108M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Revenue and profit: In fiscal 2025 revenue was $116.6M (+10.2% year on year), with net income of $9.9M. Over the 12 months to September 30, 2026: revenue $116.7M, net loss $30.1M.
Cash flow: In fiscal 2025 operations brought in $1M of cash; after $1.2M of capital spending, free cash flow was -$180K.
Latest report: The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 6, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
Next earnings report: Gyre Therapeutics, Inc.'s next report is expected around March 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Dividend: Gyre Therapeutics, Inc. declared dividends of $0.24 per share in fiscal 2022.

What Gyre Therapeutics, Inc. does

Gyre Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker GYRE.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$116.6M	$11.5M	$9.9M	$0.02	-$180K
2024	$105.8M	$16.2M	$17.9M	$0.05	-$6M
2023	$113.5M	-$67.2M	-$85.5M	-$1.41	$17.4M
2022	$102.3M	$9.2M	$4.3M	$0.03	$5.7M
2021	$7.3M	-$87.9M	-$87.9M	-$2.87	-$84.6M
2020	$20.9M	-$57.4M	-$56.2M	-$2.93	n/a

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Next report expected around March 11, 2027.

Estimated from its filing rhythm: 52 weeks after its report of March 12, 2026. Not a date the company has announced. See the report calendar · Earnings, quarter by quarter

Where GYRE ranks in Health care

Revenue$116.6M

#313 of 751 in Health care · Top 42%

Revenue growth+10.2%

#281 of 532 in Health care · Bottom 47%

Net margin8.5%

#128 of 544 in Health care · Top 23%

Free cash flow margin-0.2%

#244 of 490 in Health care · Top 50%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Dividends

Gyre Therapeutics, Inc. declared $0.24 per share in fiscal 2022. It paid out $45M in cash dividends, 1,044% of its net income.

Fiscal year	Per share	Paid out	Of profit
2022	$0.24	$45M	1,044%

Per share as declared (or paid, where only that is reported), adjusted for stock splits the company itself restated. Yield is the latest fiscal year's dividend over the current price.

Latest SEC filings

What Gyre Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

November 6, 2026
Quarterly report 10-Q · period to September 30, 2026Revenue rose 0.7% to $32.9M versus the same quarter last year; diluted EPS -$0.04 versus $0.01.
November 5, 2026
Quarterly results 8-K
October 22, 2026
Executive or director change 8-K
September 1, 2026
Investor disclosure 8-K
August 27, 2026
Employee stock plan registration S-8
August 26, 2026
Investor disclosure 8-K
August 7, 2026
Quarterly report 10-Q · period to June 30, 2026Revenue fell 2.1% to $29.1M versus the same quarter last year; diluted EPS -$0.12 versus -$0.03.
August 7, 2026
Quarterly results 8-K
July 16, 2026
Executive or director change 8-K
July 15, 2026
Quarterly results 8-K/A

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 4, 2026. Insider transactions on SEC

Insider trades

What the people running Gyre Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)

last 90 days

Sold

last 90 days

Date	Insider	What	Shares	Price	Value	Filing
June 18, 2026	Ye WeiguoChief Operating Officer	Exercised options	3,000	$0.75	$2.3K	Form 4
June 18, 2026	Ye WeiguoChief Operating Officer	Sold	3,000	$6.35	$19.1K	Form 4
June 11, 2026	Ye WeiguoChief Operating Officer	Exercised options	2,800	$0.75	$2.1K	Form 4
June 11, 2026	Ye WeiguoChief Operating Officer	Sold	2,800	$6.17	$17.3K	Form 4
June 10, 2026	Ye WeiguoChief Operating Officer	Exercised options	5,000	$0.75	$3.8K	Form 4
June 10, 2026	Ye WeiguoChief Operating Officer	Sold	5,000	$6.24	$31.2K	Form 4
June 10, 2026	Ye WeiguoChief Operating Officer	Exercised options	6,418	$0.75	$4.8K	Form 4
June 10, 2026	Ye WeiguoChief Operating Officer	Sold	6,418	$6.21	$39.9K	Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns GYRE

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
GNI USA, Inc.13D, may seek influence with 1 related filers	69.1%	86,323,015	May 6, 2026
Ying Luo13D, may seek influence with 1 related filers	8.6%	10,211,387	May 6, 2026
Ying Luo (“Mr. Luo”)13D, may seek influence with 1 related filers	8.54%	8,458,983	September 6, 2024
Songjiang Ma (“Mr. Ma”)13D, may seek influence with 1 related filers	7.62%	7,456,847	September 6, 2024
Songjiang Ma13D, may seek influence with 1 related filers	6.33%	7,342,131	May 7, 2026

Largest institutional holders

Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 60 managers reported a position.

Holder	Shares	Value	Change on quarter
HSG Holding Ltd	3,750,299	$24.7M	new
BlackRock, Inc.	993,943	$6.6M	+235,313
Octagon Capital Advisors LP	954,416	$6.3M	new
Vanguard Capital Management LLC	876,927	$5.8M	-107,277
Geode Capital Management, LLC	532,950	$3.5M	+101,536
State Street Corp	245,402	$1.6M	+29,076
Charles Schwab Investment Management Inc	184,286	$1.2M	+19,048
Northern Trust Corp	169,537	$1.1M	+35,696
SBI Securities Co., Ltd.	166,750	$1.1M	-4,087
Vanguard Fiduciary Trust Co	151,073	$995.6K	+13,391
Vanguard Portfolio Management LLC	123,953	$816.9K	+54,139
Goldman Sachs Group Inc	86,235	$568.3K	+13,113
Bank of New York Mellon Corp	62,750	$413.5K	+19,606
Morgan Stanley	41,691	$274.7K	+33,050
Alliancebernstein L.P.	24,590	$171.4K	+2,760
Strs Ohio	25,800	$170K	+4,700
Dimensional Fund Advisors LP	25,268	$166.5K	0
Nuveen, LLC	24,505	$161.5K	new
UBS Group AG	18,763	$123.6K	-2,324
Millennium Management LLC	18,488	$121.8K	new

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

2 insiders reported holding 3,265,226 shares in total, about $15.2M at the last price.

Holder	Shares	As of
Luo YingChief Executive Officer, Director	2,565,2262,565,226 held indirectly	May 6, 2026
Ye WeiguoChief Operating Officer	700,000	June 18, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about GYRE

What does Gyre Therapeutics, Inc. do?

Gyre Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as GYRE. Its shares trade on NASDAQ under the ticker GYRE.

What is Gyre Therapeutics, Inc.'s net worth?

Gyre Therapeutics, Inc. has a market value (market cap) of $518.5M at the latest share price, and shareholders' equity of $108M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is Gyre Therapeutics, Inc. profitable?

No. Over the twelve months to September 30, 2026 it reported a net loss of $30.1M on revenue of $116.7M.

How much revenue does Gyre Therapeutics, Inc. make?

Over the twelve months to September 30, 2026 Gyre Therapeutics, Inc. reported revenue of $116.7M. That is 3.8% more than a year earlier.

When did Gyre Therapeutics, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on November 6, 2026. It covers the period to September 30, 2026.

When is Gyre Therapeutics, Inc.'s next earnings report?

Gyre Therapeutics, Inc.'s next report is expected around March 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.

Does Gyre Therapeutics, Inc. pay a dividend?

Yes. Gyre Therapeutics, Inc. declared dividends of $0.24 per share in fiscal 2022.

Similar companies

Relmada Therapeutics, Inc.

AQST

Aquestive Therapeutics, Inc.

BLSM

BlossomHill Therapeutics, Inc.

CTNM

Contineum Therapeutics, Inc.

Compare GYRE with

Compare GYRE with any company

Follow GYRE

Get an email when Gyre Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Where the numbers come from

Financial figures are the values Gyre Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.